Quickly access the latest clinical recommendations [1-7] from referral through post-transplant care in this free app. Includes:
- Outcomes data and referral timing for 16 diseases
- Long-term screening tests/procedures/vaccinations
- Chronic GVHD screening by area of the body
Visit your phone's marketplace and search for "transplant" or use the links below.
Consultation timing by disease
Review disease-specific prognostic factors for patients at risk of disease progression and who should be evaluated for transplantation. Provides consultation timing recommendations for:
- AML, ALL, MDS, CML, NHL
- Hodgkin Lymphoma
- Multiple Myeloma, other Malignant Diseases, and Non-Malignant Disorders
Create customized lists of recommended post-transplant tests/procedures based on patient information. Provides recommended screening/prevention practices for transplant recipients:
- 6-months post-transplant
- 12-months post-transplant
- Annual appointments
- View recommended vaccinations for transplant recipients
- Provides vaccination schedule for all HCT recipients, both autologous and allogeneic
Chronic GVHD screening
Check potential signs/symptoms of chronic GVHD by area of the body. Includes a photo gallery of early stage GVHD symptoms
Evidence-based Reviews, developed by the American Society for Blood and Marrow Transplantation, 2003-2011. Published in Biology of Blood and Marrow Transplantation and available online at http://asbmt.org/displaycommon.cfm?an=4.
Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation; Center for International Blood and Marrow Transplant Research (CIBMTR), American Society for Blood and Marrow Transplantation (ASBMT), European Group for Blood and Marrow Transplantation (EBMT), Asia-Pacific Blood and Marrow Transplantation Group (APBMT), Bone Marrow Transplant Society of Australia and New Zealand (BMTSANZ), East Mediterranean Blood and Marrow Transplantation Group (EMBMT) and Sociedade Brasileira de Transplante de Medula Ossea (SBTMO). Co-published in Biol Blood Marrow Transplant, 2012; 18(3): 348-371; Bone Marrow Transplant, 2012; 47(3): 337–341; and Hematol Oncol Stem Cell Ther, 2012; 5(1): 1-30.
Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant. 2005; 11(12): 945-956. http://www.bbmt.org/article/PIIS1083879105006312/fulltext.
Mitchell, S.A. and Pavletic, S.Z., Measuring the therapeutic response in chronic GVHD trials: An instructional manual [CD]. Silver Spring, Md.: Palladian Partners; 2006.
These guidelines have been developed by the NMDP in consultation with Sandra A. Mitchell, CRNP, MScN, AOCN; National Institutes of Health Clinical Center; and Steven Z. Pavletic, M.D.; National Cancer Institute, National Institutes of Health, Bethesda, Md. The information in this document does not represent the official position of the NIH or the U.S. Government.
Additional Review from: Dennis L. Confer, M.D., National Marrow Donor Program, Minneapolis, Minn. Corey Cutler, M.D., Dana-Farber Cancer Institute, Boston, Mass. Stephanie J. Lee, M.D., Fred Hutchinson Cancer Research Center, Seattle, Wash.
Text and tables adapted from reports of the NIH Consensus Development Project on Criteria for Clinical Trials in Chronic GVHD with permission from Biology of Blood and Marrow Transplantation and its publisher ASBMT.
Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009; 15 :1143-1238. http://www.nature.com/bmt/journal/v44/n8/full/bmt2009254a.html
Ljungman P, Cordonnier C, Einsele H, et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant. 2009; 44: 521-526. http://www.nature.com/bmt/journal/v44/n8/full/bmt2009263a.html
Apple, the Apple logo, iPhone, iPod touch, and iTunes are trademarks of Apple Inc., registered in the U.S. and other countries. iPad is a trademark of Apple Inc. App Store is a service mark of Apple Inc.
The Trademark Blackberry® is owned by Research In Motion Limited and is registered in the United States and may be pending or registered in other counties. National Marrow Donor Program® is not endorsed, sponsored, affiliated with or otherwise authorized by Research in Motion Limited.
Android is a trademark of Google Inc. Use of this trademark is subject to Google Permissions.